User profiles for S. Attarian

Shahram Attarian

CHU La Timone , Aix-Marseille Université
Verified email at ap-hm.fr
Cited by 12256

[HTML][HTML] Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis

…, JL Berk, KP Lin, G Vita, S Attarian… - New england journal …, 2018 - Mass Medical Soc
Background Patisiran, an investigational RNA interference therapeutic agent, specifically
inhibits hepatic synthesis of transthyretin. Methods In this phase 3 trial, we randomly assigned …

European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy …

…, P Vankrunkelsven, JA Allen, S Attarian… - Journal of the …, 2021 - Wiley Online Library
To revise the 2010 consensus guideline on chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two …

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

…, MPG Stemmerik, H Andersen, S Attarian… - The Lancet …, 2021 - thelancet.com
Background There is an unmet need for treatment options for generalised myasthenia gravis
that are effective, targeted, well tolerated, and can be used in a broad population of patients…

[HTML][HTML] The neurodevelopmental impact of neonatal morphine administration

S Attarian, LC Tran, A Moore, G Stanton, E Meyer… - Brain Sciences, 2014 - mdpi.com
… Despite this, many physicians remain reluctant to administer morphine as they fear detrimental
neurological effects and are unsure of it’s role after recommendations from Bellu’s 2008 …

Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses

…, D Adams, P Latour, S Attarian - Journal of Neurology …, 2016 - jnnp.bmj.com
… will take you to the Copyright Clearance Center’s RightsLink service. You will be able to
get a … reduction of timed 10 m walk from 20 to 10 s. She subsequently became IVIg-dependent. …

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo …

…, M Saarela, M Auranen, J Pouget, S Attarian… - The Lancet …, 2018 - thelancet.com
Background Approximately two-thirds of patients with chronic inflammatory demyelinating
polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous …

Regional variation of Guillain-Barré syndrome

…, DR Cornblath, HJ Willison, Z Islam, S Attarian… - Brain, 2018 - academic.oup.com
Guillain-Barré syndrome is a heterogeneous disorder regarding the clinical presentation,
electrophysiological subtype and outcome. Previous single country reports indicate that Guillain…

European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome

…, B Avau, P Vankrunkelsven, S Attarian… - Journal of the …, 2023 - Wiley Online Library
… Shahram Attarian reports speaker honorary and travel support: LFB, Alnylam, Akcea, Pfizer,
Sanofi, Pharnext, Inflectis, Biogen, Novartis Hansa, UCB, Argenx, Alexion and Roche. Board …

Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes

…, D Figarella-Branger, N Romero, S Attarian… - Archives of …, 2007 - jamanetwork.com
… girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). …
girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). …

Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial

…, B Eymard, T Stojkovic, S Attarian, S Chevret… - Archives of …, 2005 - jamanetwork.com
Background The optimal dose of intravenous immunoglobulin (IVIG) in acute exacerbation
of myasthenia gravis remains unknown. Increasing the treatment duration might provide …